SLC22A5 and endometrial cancer: The prognosis of overall survival correlated with SLC22A5 expression was either favorable or unfavorable, depending on the type of cancer (Table 4), with the biggest impact on patients’ prognosis in pancreatic, renal and endometrial cancer.